FDA label and CMS Medicare guidance checked Oct 2026
Wegovy for MASH: The Fatty Liver Approval Explained
Wegovy has had accelerated FDA approval since Aug 15, 2025 for MASH, fatty liver with inflammation, when scarring is at stage F2 or F3 and there is no cirrhosis. At 72 weeks, 63% saw the inflammation resolve versus 34% on placebo.
- Accelerated approval
- Adults, F2 to F3 only
- Not for cirrhosis
- Medicare Part D can cover it
We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
Chia Health
Our #1 pick for GLP-1 weight loss online
- One monthly price: clinician, medication and free shipping included
- Semaglutide or tirzepatide, as a weekly injection or a daily tablet
- No insurance needed; HSA/FSA and Klarna accepted
Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure
$212.89 first month, then $349/mo
6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.
01 The approval
What the FDA Approved for Wegovy MASH
MASH, metabolic dysfunction-associated steatohepatitis, is the new name for NASH: fat in the liver plus inflammation and cell damage, which can scar the liver over years. The Wegovy label covers "noncirrhotic MASH ... with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults," with a reduced-calorie diet and more activity.
accelerated approval
no cirrhosis
1.7 mg if not tolerated
not the pill, not HD
Accelerated approval The FDA approved this use on biopsy results (less inflammation and scarring), not yet on fewer cases of cirrhosis, liver failure or transplant. The label says "continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial." ESSENCE runs to 240 weeks to answer that.
02 Trial results
ESSENCE Results at Week 72
ESSENCE randomized 800 adults 2:1 to Wegovy or placebo on top of standard care. Each had a liver biopsy at the start and at week 72, read by two pathologists. Median age was 57 and median BMI 34; 41% had a BMI of 35 or more, and 7% had a BMI under 25.
| Week 72 biopsy | Placebo (n=266) | Wegovy (n=534) | Difference (95% CI) |
|---|---|---|---|
| Steatohepatitis resolved, fibrosis not worse +29 points (21 to 36) | 34% | 63% | +29 points (21 to 36) |
| Fibrosis improved 1+ stage, steatohepatitis not worse +14 points (8 to 21) | 22% | 37% | +14 points (8 to 21) |
| Both: steatohepatitis resolved and fibrosis improved +17 points (10 to 23) | 16% | 33% | +17 points (10 to 23) |
Source: Wegovy prescribing information, section 14.4, Table 21. Novo Nordisk reports the unrounded rates as 62.9% vs 34.3% and 36.8% vs 22.4%.
Share of patients reaching each endpoint
- Resolution · placebo34%
- Resolution · Wegovy63%
- Fibrosis better · placebo22%
- Fibrosis better · Wegovy37%
Liver enzymes ALT and AST fell more on Wegovy from week 12 onward. A separate post hoc analysis of the STEP UP weight-loss trial, shown at EASD 2026, looked at liver fat (liver-fat data); it is not part of the MASH approval.
03 Eligibility
Who Qualifies for Wegovy for MASH
- 1
Adult with a MASH diagnosis. The trial required a biopsy. In practice, doctors also stage fibrosis with blood scores such as FIB-4 and liver stiffness scans such as FibroScan; ask which evidence your plan accepts.
- 2
Fibrosis stage F2 or F3. F0 to F1 (little or no scarring) and F4 (cirrhosis) are outside the label.
- 3
No BMI cutoff on the label. Unlike the weight indication, the MASH use does not name a BMI; most trial patients had obesity, and 3% had "lean MASH."
- 4
Diabetes is allowed. 56% of ESSENCE patients had type 2 diabetes. Wegovy is not combined with Ozempic or another GLP-1.
- 5
No medullary thyroid cancer or MEN 2 in you or your family, per the label contraindications.
Ro's insurance concierge checks Wegovy coverage and files the prior authorization. Ro Body membership $74 to $149 a month, medication billed separately (Oct 2026).
Have Ro check your Wegovy coverage04 Insurance
Wegovy MASH Insurance and Medicare
MASH is a liver diagnosis, so a weight-loss exclusion does not automatically apply. UnitedHealthcare, for example, covers Wegovy injection for MASH with prior authorization under the same policy as heart risk, on plans that exclude weight loss (UnitedHealthcare). Other plans: Aetna, Cigna, Blue Cross.
Medicare Part D
CMS lists noncirrhotic MASH with moderate to advanced fibrosis as a Part D use. Your plan's formulary copay and prior authorization apply.
Not the $50 Bridge
CMS says people with this diagnosis are ineligible for the GLP-1 Bridge, even if their Part D plan does not cover the drug. See Medicare GLP-1 Bridge.
Commercially insured and approved? The Wegovy savings card can bring a fill to as little as $25 (maximum savings $100 a month). Without coverage, NovoCare self-pay is $349/mo for the pen; the MASH dose costs the same as lower doses. More: Wegovy cost.
05 Safety
Side Effects and Liver Safety
Side effects are the usual semaglutide ones, mostly nausea, diarrhea, constipation and vomiting during the dose climb. Label warnings include pancreatitis, gallbladder disease, acute kidney injury from dehydration and the thyroid C-cell boxed warning. Gallbladder problems matter more with liver disease, so report pain in the upper right abdomen. Full list: Wegovy side effects.
06 FAQ
Wegovy MASH FAQ
Is Wegovy FDA-approved for fatty liver disease?
What does accelerated approval mean for Wegovy MASH?
How well does Wegovy work for MASH?
Does Medicare cover Wegovy for MASH?
Is the Wegovy pill approved for MASH?
Are there other FDA-approved drugs for MASH?
Other approved uses: what GLP-1 is used for · Wegovy for heart risk · Zepbound for sleep apnea.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Last updated Oct 29, 2026 · trial figures from the Wegovy label (06/2026) · Medicare rules from CMS · prices from NovoCare, Oct 2026.
References
- Wegovy (semaglutide) Prescribing Information, revised 06/2026, sections 1, 2.2, 14.4 (Tables 20 and 21), checked 2026-10-23, Novo Nordisk / FDA, 2026
- Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis, Aug 15, 2025, Novo Nordisk US, 2025
- Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 2025;392:2089-2099, New England Journal of Medicine, 2025
- Drugs@FDA: Wegovy, NDA 215256 supplement 024 (MASH), Aug 15, 2025, U.S. Food and Drug Administration, 2025
- Medicare GLP-1 Bridge: information for Part D plans, checked 2026-10-23, Centers for Medicare & Medicaid Services, 2026
- Prior Authorization/Non-Formulary: Wegovy, Cardiovascular Risk Reduction and MASH Only, 2026 P 1445-4, effective May 1, 2026, UnitedHealthcare Pharmacy, 2026
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease (Rezdiffra), Mar 14, 2024, U.S. Food and Drug Administration, 2024
- Wegovy self-pay and savings offer, checked 2026-10-16, NovoCare, 2026